Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 45-50

  Li, Yi ^a   Huang, Yusheng ^a   Lv, Yangfan ^a   Meng, Gang ^a   Guo, Qiao Nan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 Aza CdR; Methylation; Osteosarcoma; TSSC3

Indexed keywords

5-AZA-CDR; METHYLATION; OSTEOSARCOMA; TSSC3;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BONE NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NUCLEAR PROTEINS; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84895071675     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.10.006     Document Type: Article

References (30)

1. Bacci G., Ferrari S., Longhi A., Picci P., Mercuri M., Alvegard T.A., et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002, 14:198-206.
2. Kawaguchi K., Oda Y., Sakamoto A., SaitoT, Tamiya S., Iwamoto Y., et al. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 2002, 15:878-888.
3. Benassi M.S., Molendini L., Gamberi G., Magagnoli G., Ragazzini P., Gobbi G.A., et al. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 2001, 92:3062-3067.
4. Khatib H. Is it genomic imprinting or preferential expression?. Bioessays 2007, 29:1022-1028.
5. Li Y., Meng G., Guo Q.N. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 2008, 84:234-239.
6. Lee M.P., Feinberg A.P. Genomic imprinting of a human apoptosis gene homologue TSSC3. Cancer Res 1998, 58:1052-1056.
7. Schwienbacher C., Angioni A., Scelfo R., Veronese A., Calin C.A., Massazza G., et al. Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumor. Cancer Res 2000, 60:1521-1525.
8. Thaker H.M., Berlin A., TyckoB, GoldsteinDP, Berkowitz R.S., Castrillon D.H., et al. Immunohistochemistry for the imprinted gene product IPL/PHLDA2 for facilitating the differential diagnosis of complete hydatidiform mole. J Reprod Med 2004, 49:630-636.
9. Frank D., Fortino W., ClarkL, Musalo R., Wang W., Saxena A., et al. Placental overgrowth in mice lacking the imprinted gene Ipl. Proc Natl Acad Sci U S A 2002, 99:7490-7495.
10. Müller S., Van Den Boom D., Zirkel D., Köster H., Berthold F., Schwab M., et al. Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors. Hum Mol Genet 2000, 9:757-763.
11. Dai H., Huang Y., Li Y., Meng G., Wang Y., Guo Q.N. TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma. Carcinogenesis 2012, 33(1):30-40.
12. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
13. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
14. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
15. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005, 23:3948-3956.
16. de Vos D., van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005, 84(Suppl.1):3-8.
17. Stresemann C., Brueckner B., Musch T., Stopper H., Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006, 66:2794-2800.
18. Rudek M.A., Zhao M., He P., Hartke C., Gilbert J., Gore S.D., et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005, 23:3906-3911.
19. Holleran J.L., Parise R.A., Joseph E., Eiseman J.L., Covey J.M., Glaze E.R., et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005, 11:3862-3868.
20. Ando T., Ichikawa J., Okamoto A., Tasaka K., Nakao A., Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005, 23:964-969.
21. Bender C.M., Pao M.M., Jones P.A. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998, 58:95-101.
22. Rahnama F., Shafiei F., Gluckman P.D., Mitchell M.D., Lobie P.E. Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 2006, 147:5275-5283.
23. Razin A., Kantor B. DNA methylation in epigenetic control of gene expression. Prog Mol Subcell Biol 2005, 38:151-167.
24. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
25. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantarjian H.M., et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002, 8:2217.
26. Daskalakis M.M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
27. Qian N., Frank D., O'Keefe D., Dao D., Zhao L., Yuan L., et al. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet 1997, 6:2021-2029.
28. Neef R., Kuske M.A., Pröls E., Johnson J.P. Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 2002, 62:5920-5929.
29. Nagai M.A., Fregnani J.H., Netto M.M., Brentani M.M., Soares F.A. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 2007, 106:49-56.
30. Keane M.M., Ettenberg S.A., Lowrey G.A., Russell E.K., Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996, 56:4791-4798.